8-K: Modular Medical Prices $4.68M Public Offering of Stock and Warrants

Modular Medical, an insulin delivery technology company, announced the pricing of a $4.68 million public offering of common stock and accompanying warrants to fund operations and working capital.

Summary

• Modular Medical, Inc. priced an underwritten public offering of 12,173,000 shares of common stock and warrants exercisable to purchase up to 6,086,500 shares of common stock.
• The combined offering price is $0.77 for two shares of common stock and one accompanying warrant, yielding an effective price of $0.38 per share and $0.01 per warrant.
• The warrants have an exercise price of $0.45 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance.
• Gross proceeds to the company from the offering are expected to be approximately $4.68 million, before deducting underwriting discounts and offering expenses.
• Newbridge Securities Corporation is acting as the sole bookrunner for the offering.
• The company granted the underwriter a 30-day option to purchase up to an additional 15% of the common shares and/or warrants sold in the offering to cover over-allotments.
• The offering is expected to close on December 11, 2025.
• Net proceeds from the offering are intended to fund operations, working capital, and general corporate purposes, including capital expenditures.

Sentiment

Score: 6

Explanation: The offering successfully secures capital for the company's operations and strategic goals, which is positive for its long-term viability. However, the significant dilution for existing shareholders and the relatively low effective share price are notable drawbacks. The capital raise is essential for a development-stage medical device company, but the terms reflect market conditions and the company's current valuation.

Positives

• Secured approximately $4.68 million in gross proceeds, providing essential capital for funding operations, working capital, and general corporate purposes, including capital expenditures.
• The capital raise strengthens the company's financial position to support the development and potential launch of its insulin delivery technology.
• The inclusion of a 30-day over-allotment option for the underwriter indicates potential for additional capital if there is strong market demand for the securities.

Negatives

• The issuance of 12,173,000 shares of common stock and warrants to purchase 6,086,500 shares will result in significant dilution for existing shareholders.
• The effective price of $0.38 per share and $0.01 per warrant, at a combined price of $0.77 for two shares and one warrant, reflects a relatively low valuation for the capital being raised.
• Underwriting discounts and commissions of 7% of gross proceeds, along with up to $85,000 in reimbursed expenses, will reduce the net proceeds received by the company.

Risks

• Forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different, including whether or when the offering may be completed, the expected closing date, and the actual use of proceeds.
• Other risk factors and business considerations are described in Modular Medical's SEC filings, including its annual report on Form 10-K.
• The Underwriter has the right to terminate the Underwriting Agreement under various conditions, such as material disruption of general securities markets, suspension of trading, new wars or major hostilities, banking moratoriums, material adverse changes to the company, or a material breach of company covenants.
• The Underwriter Warrant is subject to significant restrictions on transfer for 180 days following the date of the Prospectus Supplement, as per FINRA Rule 5110.

Future Outlook

The company intends to use the net proceeds from the offering to fund operations and for working capital and general corporate purposes, including capital expenditures. Forward-looking statements are subject to risks and uncertainties, including the completion of the offering and the actual use of proceeds.

Management Comments

• Modular Medical, Inc. (Nasdaq: MODD), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult almost-pumpers with its user-friendly and affordable design, today announced that it has commenced an underwritten public offering...
• Its mission is to improve access to the highest standard of glycemic control for people with diabetes, taking it beyond superusers and providing diabetes care for the rest of us.
• Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump.

Industry Context

Modular Medical operates in the medical device industry, specifically focusing on insulin delivery technology. Its product, an FDA-cleared patch pump, aims to address a broader market of 'almost-pumpers' by offering a user-friendly and affordable design, potentially expanding access to advanced glycemic control beyond traditional 'superusers' of insulin pumps. This strategy positions the company to potentially disrupt the existing insulin pump market by targeting a segment that may be underserved by current complex or expensive solutions.

Corporate Governance

Stakeholder Impact

• Shareholders: Existing shareholders will experience dilution due to the issuance of new common stock and warrants. The capital raise provides funding for future growth, which could benefit shareholders long-term, but the immediate impact is dilution.
• Employees: The capital raise provides financial stability, potentially securing jobs and supporting ongoing development efforts for the company's insulin delivery technology.
• Customers: The funding supports the company's mission to launch and improve access to its insulin delivery technology, potentially benefiting future customers with an affordable and user-friendly patch pump.
• Creditors: The capital raise improves the company's liquidity and financial health, potentially reducing risk for creditors.

Next Steps

• The offering is expected to close on December 11, 2025.
• The company will use the net proceeds to fund operations, working capital, and general corporate purposes, including capital expenditures.
• The company has agreed to issue an Underwriter Warrant on the Closing Date and each Over-allotment Option Closing Date, if any.
• The company will use its commercially reasonable efforts to maintain the listing of its Common Stock on The Nasdaq Capital Market (NasdaqCM) for at least two years.
• The company will continue to file periodic reports with the SEC and furnish them to the Underwriter.
• The company will use commercially reasonable efforts to cause the Registration Statement to remain effective with a current prospectus until the latest of nine months after the Applicable Time, the date the Warrants have been exercised in full or expired, and the date the Underwriter's Warrant has been exercised in full or expired.

Key Dates

Recommendation

The capital raise provides essential funding for Modular Medical's operations and product development, which is crucial for a medical device company in its growth phase. This infusion of capital mitigates immediate liquidity concerns and supports the company's strategic objectives, including the launch of its FDA-cleared patch pump. However, the significant dilution from the offering, coupled with the relatively low effective share price, presents a near-term headwind for existing shareholders. While the long-term potential of its insulin delivery technology is promising, the immediate impact of dilution and the need for the company to execute on its commercialization strategy warrant a 'hold' recommendation. Investors should monitor the company's progress in deploying this capital and achieving market penetration with its product.

Keywords

Modular Medical, MODD, Public Offering, Common Stock, Warrants, Insulin Delivery, Medical Device, Capital Raise, SEC Filing, Nasdaq, Newbridge Securities